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spoligotyping and mycobaterial interspersed repetitive unit
(MIRU) typing. Beijing ancient strains and Harrlem strains
predominated among aborigines, while Beijing modern
strains were common among veterans and the general
population. All Beijing strains were further analyzed by
typing the NTF loci and RD deletion. Results suggest
a chronological trend among Beijing isolates from the
three groups: isolates from the aborigines had signatures
compatible with ancient lineages, and those from veterans
and the general population were more contemporary. Our
data indicate that the distribution of MTB genotypes/strains
in Taiwan is associated with different populations whose
migratory activities occurred between 55 and 500 years
ago. These results suggest that transmission of MTB may
have been relatively restricted to close contacts.
Part II study: A total of 356 MTB isolates were analyzed
for the genotypes of MTB in metropolitan city. Major
spoligotypes found were Beijing lineages (52.5%), followed
by Haarlem lineages (13.5%) and EAI plus EAI-like lineages
(11%). When MIRU-VNTR was employed, 140 patterns were
identiﬁed, including 36 clusters by 252 isolates and 104
unique patterns, and the largest cluster comprised 95
isolates from the Beijing family. The combination of
spoligotyping and MIRU-VNTR revealed that 236 (67%) of
the 356 isolates were clustered in 43 genotypes, and thus
the proportion of TB infection that can be considered due
to the recent transmission is estimated (236 43)/356 = 54%.
Patients infected with Beijing strains were younger than
those with other strains. Moreover, infected persons younger
than 25 years had Beijing modern stain, suggesting a possible
recent spread in the young population by this family of TB
strain in Taipei.
Conclusion: The distribution of MTB in Taiwan is closely
associated with the ethnicity and migratory population
at different historical periods. The high clustering of
MTB isolates and the high prevalence of Beijing family
strains in young persons strongly indicate that a stringent
control policy should be taken in Taiwan, particularly in
metropolitan city.
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Microscopy is still the backbone and benchmark of
laboratory diagnostics in TB, but it is well recognized
that better technical approaches are urgently needed to
overcome limitations in test sensitivity, time to result and
ease of use. The ultimate alternative products are expected
to provide rapid testing in primary care settings. To this end
a number of opportunities are being followed up, ranging
from identiﬁcation of novel biomarkers for various stages
of disease to the development of enabling technologies
suited for implementation in the different sectors of the
health care system in developing countries, i.e., from the
reference laboratory down to the health post in rural areas
where the biggest gaps exist.
It has become widely accepted that resolution of open
issues in TB diagnostics can only be achieved by systematic
and novel research approaches. Among these are the
seroproﬁling of the whole M. tuberculosis proteome using
antigen arrays, discovery of marker molecules in sputum
and urine employing most advanced mass spectrometry.
Both development programs are progressing at fast pace.
In addition, two rapid molecular detection systems have
been developed and are close to entering international
evaluation studies: an assay developed by Eiken Chemicals
represents the ﬁrst manual molecular TB test emplyoing
rapid DNA ampliﬁcation based on LAMP technology whereas
the GeneXpert platform from Cepheid, Inc. provides fully
automated point of care Mtb DNA detection by rtPCR at
an ultrasensitive level. These technology approaches are
considered breakthrough diagnostics that for the ﬁrst time
will enable robust Mtb nucleic acid detection in fast and
affordable formats.
The recent introduction and WHO endorsement of
technologies such as liquid culture, rapid speciation and
molecular DST demonstrate that our current approaches
are effective and already show their impact. These
achievements will be furter complemented by the
introduction of iLED, a low cost ﬂuorescence microscope
that will signiﬁcantly incraese sensitivity of sputum smear
analysis.
However, it is also clear that those achievements all
based on private-public-partnerships were only made
possible by implementing a strong industry-type quality and
project management system as an ultimate prerequisite for
successful product development. Using available, leading
edge tools in biomarker discovery, detection technology
and project management, we are now in an excellent
position to further narrow and even close current gaps
in TB diagnostics.
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Molecular tests have brought a signiﬁcant impact on
laboratory diagnosis of tuberculosis (TB) from simple
detection of Mycobacterium tuberculosis from clinical
specimens to rapid detection of MDR/XDR-TB. As an effort
to implement those tests to clinical mycobacteriology
laboratories, we also have been working on developing
and evaluation various molecular techniques using clinical
samples and mycobacterial cultures.
Firstly, we tried to detect M. tuberculosis-speciﬁc DNA
in sputum samples by polymerase chain reaction (PCR),
and target DNAs were IS6110, region of deletions (RDs),
and the rpoB gene, etc. Since the proportion of non-
tuberculous mycobacteria (NTM) has increased in many
countries, we also developed molecular tests, in which
primer sets detecting both M. tuberculosis and NTMs were
included and evaluated them using sputum samples and
mycobacterial cultures from both solid and liquid culture
systems.
Secondly, we developed a series of molecular tests
for identiﬁcation of Mycobacterium species. Initially, we
employed a PCR-restriction enzyme analysis (PRA) targeting
a polymorphic region of the rpoB gene. Using the PRA, we
were able to differentiate more than 50 Mycobacterium
species. Mycobacterium species-speciﬁc probes were then
designed and used in a dot-blot assay and a reverse-blot
hybridization assay (RBHA). At least 13 Mycobacterium
species, covering more than 95% of mycobacteria from
clinical samples in Korea, were successfully identiﬁed either
by dot-blot or by RBHA.
Thirdly, we explored the dot-blot assay and RBHA to detect
mutations of genes associated with resistance to anti-TB
drugs, both the ﬁrst and second line drugs. As appeared in
numerous literatures, we found the in-house made RBHA
is working properly for detecting mutations at katG, inhA,
and ahpC genes for resistance to INH, at the rpoB gene
to RIF, at the rrs and rpsL genes to SM, KAN, AMK, and
CAP, and the gyrA gene to OFX. Although there is still a
substantial portion of M. tuberculosis isolates which do not
have mutations at these genes, RBHA has been useful in
reducing turn-around time substantially for rapid detection
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of anti-TB drug resistance both from smear-positive sputum
samples and cultures. Recently, we developed RBHAs for
detection of mutations at the gyrA gene and at the rrs and
rpsL genes, which are responsible for XDR-TB.
Lastly, we developed an RBHA-based dual test for TB/NTM
identiﬁcation and detection of mutations at the rpoB gene,
which are the most critical information of MDR-TB using one
set of primers. This was possible because the polymorphic
regions for Mycobacterium species identiﬁcation and for
mutations involved in resistance to RIF are located closed
within 360 bp.
Throughout our exercises in evaluating these molecular
diagnostic tests, we found advantages and problems
in implementing them to the clinical mycobacteriology
laboratories, and these points will be discussed with
numerous examples.
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Background: Tuberculosis (TB) remains one of the major
public health problems worldwide, with 95% of cases and
98% of deaths occurring in developing countries. According
to the epidemiological surveillance carried out in 2000,
approximately 550 million individuals in China have been
infected with Mtb. based on the result of TST. Nevertheless,
TST has been shown inferior to Interferon-Gamma Release
Assay (IGRA) in terms of the speciﬁcity and sensitivity as
reported in countries with low incidence of tuberculosis.
Therefore, both the diagnostic value of IGRA in the setting
of china and the number of Mtb. infection determined by
IGRA warrant investigation.
Objectives: (1) To evaluate the sensitivity and speciﬁcity
of an in-house Mtb. speciﬁc IFN-g Elispot kit in diagnosis
of Mtb. infection. (2) To investigate the prevalence of Mtb.
infection in different population using the in-house Elispot
kit.
Methods: By screening the IFN-g response to different
antigen proteins (eg. recombinant ESAT-6 protein) and
individual peptides derived from Mtb. antigens, an in-
house IFN-g Elispot kit was developed. The sensitivity
and speciﬁcity of the in-house Elispot kit in diagnosis of
tuberculosis were evaluated in paralleled comparison with
commercial Quantiferon-TB-Gold. The prevalence of Mtb.
infection in different healthy populations in Shenzhen was
investigated using the in-house Elispot kit and compared
with TST.
Results: The sensitivity and speciﬁcity of in-house Elispot kit
for diagnosis of tuberculosis were 86% and 92%, respectively,
both of which are comparable with the commercial
Quantiferon-TB-Gold and signiﬁcantly higher than TST. In
addition, the price of in-house Elispot kit was only about
1/4 of commercial kits such as Qunatiferon-TB-Gold or
T.SPOT.TB. Using the Elispot assay, the prevalence of Mtb.
infection in healthy population varied from 5.88% to 55.6%
depends on their exposure to active tuberculosis cases.
Conclusion: An in-house affordable IGRA kit for diagnosis
of Mtb. infection has been developed with sensitivity
and speciﬁcity comparable to that of commercial kits.
The prevalence of Mtb. infection in healthy population
determined by IGRA is signiﬁcantly lower than that of TST.
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Insulin resistance (IR) is more often seen in chronic hepatitis
virus C infection than in other forms of chronic liver
disease. Recent research indicates that IR seen in patients
chronically infected with HCV may be directly caused or
at least favoured by the virus itself. In the transgenic
mice model the HCV core protein has been shown to
induce IR as a consequence of increased TNF production.
Other mechanisms have been also proposed, based on the
activation of a number of cytokines, and on generation
of oxidative stress, as consequence of the direct effect
of the HCV and of HCV proteins on mitochondria and
on the hepatocyte endoplasmic reticulum. Recent results
obtained in our laboratory implicate endogenous interferon
production in HCV related IR due to common intracellular
signalling shared by interferon and insulin.
IR has a number of clinical consequences in hepatitis C.
It associates with more rapid progression of ﬁbrosis and
with reduced response to antiviral therapy with interferon
or peghilated-interferon and ribavirin. The mechanisms
by which IR promotes ﬁbrosis progression in the liver
of patients with HCV include: development of hepatic
steatosis, hyperleptinemia, increased TNF production and
reduce expression of PPARg receptors. These concepts have
practical implications for the management of patients with
HCV, and diet and exercise aimed to reduce metabolic
abnormalities should be recommended, particularly in
overweighted cases.
Several studies have clearly demonstrated that sustained
virological response to interferon-based therapy is
signiﬁcantly reduced in patients with HCV and high
Homeostasis Model of Assessment (HOMA) IR index. This
effect is independent of presence of type 2 diabetes and
of obesity and is already evident with HOMA values >3.
We have recently shown that baseline hyperinsulinemia has
inhibitory effects on serum HCV-RNA decay seen as early as
24 hours after the ﬁrst injection of pegylated-interferon,
indicating direct downregulation by insulin of intracellular
IFN signalling. The impairment of the early antiviral
response correlate with reduces sustained response to PEG-
IFN plus ribavirin treatment. Several studies have now
conﬁrmed reduced SVR in patients with IR, independently
of the HCV genotype. Interestingly patients with SVR
experienced a signiﬁcant reduction in the HOMA index
that returned within the normal range at the time of HCV
clearance, suggesting a direct relationship between HCV
replication and IR.
Obviously IR seen in patients with HCV is not always related
to direct effects of HCV and may also occur as consequence
of the classical metabolic syndrome frequently seen in the
general population, particularly in the Western civilized
countries. However, also in these cases IR is associated
with more progressive liver disease and reduces response to
antiviral therapy and should be therefore corrected when
possible.
Ongoing studies are assessing the role of insulin sensitisers
(metformine, pioglitazone) for improving the response to
antiviral therapy in HCV patients with IR, but results so far
reported have been controversial and inconclusive.
